ONC201 in previously-irradiated pediatric H3 K27M-mutant glioma

Sharon L. Gardner; Jeffrey C. Allen; Wafik Tharwat Zaky; Yazmin Odia; Doured Daghistani; Ziad Khatib; Carl Johannes Koschmann; Dolly Aguilera; Tobey J. MacDonald; Andrew S. Chi; Rohinton Tarapore; Krystal Merdinger; Wolfgang Oster; Joshua E. Allen; Soumen Khatua

doi:10.1200/jco.2019.37.15_suppl.10046

ONC201 in previously-irradiated pediatric H3 K27M-mutant glioma

Sharon L. Gardner, Jeffrey C. Allen, Wafik Tharwat Zaky, Yazmin Odia, Doured Daghistani, Ziad Khatib, Carl Johannes Koschmann, Dolly Aguilera, Tobey J. MacDonald, Andrew S. Chi, Rohinton Tarapore, Krystal Merdinger, Wolfgang Oster, Joshua E. Allen, Soumen Khatua

Research output: Contribution to conference › Presentation

Original language	American English
DOIs	https://doi.org/10.1200/jco.2019.37.15_suppl.10046
State	Published - 2019
Event	ASCO 2019 - Duration: Jan 1 2019 → …

Conference

Conference	ASCO 2019
Period	1/1/19 → …

Disciplines

Medicine and Health Sciences
Neoplasms
Neurology
Oncology

Access to Document

10.1200/jco.2019.37.15_suppl.10046License: Unspecified

Cite this

@conference{6c2343a56c944f438ac67ba33a6bf6ac,

title = "ONC201 in previously-irradiated pediatric H3 K27M-mutant glioma",

author = "Gardner, {Sharon L.} and Allen, {Jeffrey C.} and Zaky, {Wafik Tharwat} and Yazmin Odia and Doured Daghistani and Ziad Khatib and Koschmann, {Carl Johannes} and Dolly Aguilera and MacDonald, {Tobey J.} and Chi, {Andrew S.} and Rohinton Tarapore and Krystal Merdinger and Wolfgang Oster and Allen, {Joshua E.} and Soumen Khatua",

note = "10046 Background: ONC201 is the first DRD2 antagonist for clinical oncology. The recommended phase 2 dose (RP2D) of 625mg ONC201 orally once a week has been established in adult patients. ONC201 efficacy has been shown in high-grade glioma preclinical models and radiographic regressions with single agent ONC201 have been reported in adult recurrent H3 K27M-mutant glioma patients.; ASCO 2019 ; Conference date: 01-01-2019",

year = "2019",

doi = "10.1200/jco.2019.37.15_suppl.10046",

language = "American English",

}

TY - CONF

T1 - ONC201 in previously-irradiated pediatric H3 K27M-mutant glioma

AU - Gardner, Sharon L.

AU - Allen, Jeffrey C.

AU - Zaky, Wafik Tharwat

AU - Odia, Yazmin

AU - Daghistani, Doured

AU - Khatib, Ziad

AU - Koschmann, Carl Johannes

AU - Aguilera, Dolly

AU - MacDonald, Tobey J.

AU - Chi, Andrew S.

AU - Tarapore, Rohinton

AU - Merdinger, Krystal

AU - Oster, Wolfgang

AU - Allen, Joshua E.

AU - Khatua, Soumen

N1 - 10046 Background: ONC201 is the first DRD2 antagonist for clinical oncology. The recommended phase 2 dose (RP2D) of 625mg ONC201 orally once a week has been established in adult patients. ONC201 efficacy has been shown in high-grade glioma preclinical models and radiographic regressions with single agent ONC201 have been reported in adult recurrent H3 K27M-mutant glioma patients.

PY - 2019

Y1 - 2019

UR - http://dx.doi.org/10.1200/jco.2019.37.15_suppl.10046

U2 - 10.1200/jco.2019.37.15_suppl.10046

DO - 10.1200/jco.2019.37.15_suppl.10046

M3 - Presentation

T2 - ASCO 2019

Y2 - 1 January 2019

ER -

ONC201 in previously-irradiated pediatric H3 K27M-mutant glioma

Conference

Disciplines

Access to Document

Other files and links

Cite this